Biosimilar Market in India: the Approaching of the Expiration of Herceptin Patent in India
Roche’s patent on Herceptin will soon expire in India, thus today here we briefly talk about the biosimilar market in India regarding this.
According to authority information, there is still no clear trend if the local pharmaceuticals start to “march” to biosimilar market.
Digging the reason, one may be that it is unclear if the local government cancels the patent thus biosimilar win a chance. Another reason may be that if the local pharmaceuticals have the ability to develop high-efficient Herceptin biosimilars.
For example, in 2010, Cipla, an India company, attempted to launch unauthorized Herceptin and other cancer biosimilars which later was proved to be greatly inferior to Herceptin in terms of potency by World Health Organization. This seems to tell us that it is still difficult for India to make equal biosimilar to Herceptin.
In conclusion, there are still some obstacles for India pharmaceuticals manufacture such knockoffs and it needs some time for India biosimilars grow.